Assessment of Optimal Size and Composition of the U.S. National Registry of Hematopoietic Stem Cell Donors
Craig Kollman(Diabetes Australia), Michelle Setterholm(National Marrow Donor Program), Thomas J. Smith(Sidney Kimmel Cancer Center), Carolyn Katovich Hurley(Georgetown University), Robert L. Baitty(Health Resources and Services Administration), John A. Nyman(Park Nicollet Health Services), Ranajit Chakraborty(Georgetown University), Edgar L. Milford(Brigham and Women's Hospital), Robert J. Hartzman(National Marrow Donor Program), Patrick G. Beatty(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Randal K. Wada(National Marrow Donor Program), Esteban Abella(Children's Hospital of Michigan), Galen E. Switzer(University of Pittsburgh)
Cited by 112
Related Papers
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
|New England Journal of Medicine|1986|1.5k
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
|Journal of Clinical Oncology|2003|1.4k
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
|New England Journal of Medicine|2019|960
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2009|913
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
|Journal of Clinical Oncology|2015|903